Clinical Characteristics and Risk Factors for Persistent Thrombocytopenia among Pediatric Patients after Bone Marrow Transplant in Saudi Arabia: A 3-Year Retrospective Observational Analysis from Tertiary Hospital
- 1*,
- 2,
- 3,
- 3,
- 1
- 1Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, SAUDI ARABIA.
- 2Department of Clinical Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, SAUDI ARABIA.
- 3Department of Clinical Pharmacy, Northern Border University, Arar, SAUDI ARABIA.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Mohammed Kanan
Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, SAUDI ARABIA.
Email: ii_kanan101@outlook.com
Copyright: © 2025 The Author(s). This is an open access article.
Published: Jan 1, 2025, Received: Aug 27, 2024, Accepted: Nov 6, 2024
Abstract
Background: Bone marrow transplantation (BMT) is a crucial treatment for pediatric patients with various hematological, oncological, and genetic diseases. However, persistent thrombocytopenia (PT) post-transplantation poses a significant challenge, affecting recovery and prognosis. Objectives: This study aimed to identify the clinical characteristics and risk factors associated with PT in pediatric patients post-BMT, specifically in Saudi Arabia. Materials and Methods: A retrospective cohort study design was employed, involving pediatric patients who underwent BMT between January 2020 and January 2023. Clinical characteristics, laboratory results, treatment data, and outcomes were collected from electronic medical records. Logistic regression analyses were conducted to identify risk factors associated with PT. Results: Among the 77 pediatric patients in the study, no significant differences were observed in demographic characteristics, transplant types, or treatment modalities between early-onset and late-onset thrombocytopenia groups. However, the duration of thrombocytopenia post-transplant differed significantly between the groups, with early-onset cases experiencing shorter durations. Infections and graft-versus-host disease were common post-transplant complications. Chemotherapy and antiviral therapy were frequently administered treatments. Pediatric patients undergoing BMT are susceptible to PT, with varying durations based on the onset timing. Conclusion: The study emphasizes the importance of risk assessment and tailored management to mitigate thrombocytopenia in pediatric BMT patients. Further research is needed to elucidate the underlying mechanisms and optimize therapeutic interventions for thrombocytopenia in this population.
Keywords
Subject
Recommended articles
- Mechanism Underlying Linezolid‑induced Thrombocytopenia in a Chronic Kidney Failure Mouse Model
Nao Nishijo, Yasuhiro Tsuji, Kazuhisa Matsunaga · Journal of Pharmacology and Pharmacotherapeutics
- Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study
Jose Francis, Muthiah Palaniappan, Biswajit Dubashi · Journal of Pharmacology and Pharmacotherapeutics
- Clozapine associated thrombocytopenia
Natasha Kate, Sandeep Grover, Munish Aggarwal · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026